Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03888365 · ClinicalTrials.gov registry record
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
A clinical trial, sponsored by United Therapeutics.
- Completed
- Registry status
- 43
- Enrollment target
NCT03888365 is a clinical trial that has completed, run by United Therapeutics. The registered enrollment target is 43 participants.
The verdict
NCT03888365 has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
This is an observational, multicenter, single-day, Phase 2 study. This study will include a 14-day Screening Period and Study Day 1 clinic visit. Participants will be required to perform an activity to induce symptoms of PAH, and participants' severity of self-reported symptoms of PAH will be measured from pre-activity, immediately after the activity, and through the 30-minute recovery. Participants will be asked about their PAH symptoms using 3 PGI-S questions that address their overall PAH symptoms, shortness of breath, and physical fatigue.
Interventions
- DRUG Treprostinil
- DRUG Non-Treprostinil PAH Medications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2019-09-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03888365
The ClinicalTrials.gov registry entry for NCT03888365 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treprostinil is the first listed.
NCT03888365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03888365 about?
NCT03888365 is a clinical study titled "Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH". This is an observational, multicenter, single-day, Phase 2 study. This study will include a 14-day Screening Period and Study Day 1 clinic visit. Participants will be required to perform an activity to induce symptoms of PAH, and participants' severity of self-reported symptoms of PAH will be measur...
What is the current status of trial NCT03888365?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2019-04-01. Estimated completion is 2019-09-19.
What interventions are being tested in trial NCT03888365?
The interventions under investigation include: Treprostinil (DRUG), Non-Treprostinil PAH Medications (DRUG).
Who is sponsoring clinical trial NCT03888365?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.